Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention

Matthew T. Roe; John C. Messenger; William S. Weintraub; Christopher P. Cannon; Gregg C. Fonarow; David Dai; Anita Y. Chen; Lloyd W. Klein; Frederick A. Masoudi; Charles McKay; Kathleen Hewitt; Ralph G. Brindis; Eric D. Peterson; John S. Rumsfeld

doi:10.1016/j.jacc.2010.05.008

Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention

Matthew T. Roe, John C. Messenger, William S. Weintraub, Christopher P. Cannon, Gregg C. Fonarow, David Dai, Anita Y. Chen, Lloyd W. Klein, Frederick A. Masoudi, Charles McKay, Kathleen Hewitt, Ralph G. Brindis, Eric D. Peterson, John S. Rumsfeld

Research output: Contribution to journal › Article › peer-review

355 Scopus citations

Original language	English (US)
Pages (from-to)	254-263
Number of pages	10
Journal	Journal of the American College of Cardiology
Volume	56
Issue number	4
DOIs	https://doi.org/10.1016/j.jacc.2010.05.008
State	Published - Jul 20 2010
Externally published	Yes

Keywords

NCDR
acute myocardial infarction
percutaneous coronary intervention

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2010.05.008

Cite this

Roe, M. T., Messenger, J. C., Weintraub, W. S., Cannon, C. P., Fonarow, G. C., Dai, D., Chen, A. Y., Klein, L. W., Masoudi, F. A., McKay, C., Hewitt, K., Brindis, R. G., Peterson, E. D., & Rumsfeld, J. S. (2010). Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. Journal of the American College of Cardiology, 56(4), 254-263. https://doi.org/10.1016/j.jacc.2010.05.008

Roe, MT, Messenger, JC, Weintraub, WS, Cannon, CP, Fonarow, GC, Dai, D, Chen, AY, Klein, LW, Masoudi, FA, McKay, C, Hewitt, K, Brindis, RG, Peterson, ED & Rumsfeld, JS 2010, 'Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention', Journal of the American College of Cardiology, vol. 56, no. 4, pp. 254-263. https://doi.org/10.1016/j.jacc.2010.05.008

@article{5011538b69094d1a85588a811d7b2145,

title = "Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention",

keywords = "NCDR, acute myocardial infarction, percutaneous coronary intervention",

author = "Roe, {Matthew T.} and Messenger, {John C.} and Weintraub, {William S.} and Cannon, {Christopher P.} and Fonarow, {Gregg C.} and David Dai and Chen, {Anita Y.} and Klein, {Lloyd W.} and Masoudi, {Frederick A.} and Charles McKay and Kathleen Hewitt and Brindis, {Ralph G.} and Peterson, {Eric D.} and Rumsfeld, {John S.}",

note = "Funding Information: Dr. Roe has received research funding from Eli Lilly , Bristol-Myers Squibb , Sanofi-Aventis , and Merck/Schering-Plough ; and consulting fees/honoraria from GlaxoSmithKline, Novartis, Eli Lilly, Bristol-Myers Squibb, Sanofi-Aventis, Merck/Schering-Plough, and AstraZeneca. Dr. Messenger is a Principal Investigator for the Resolute substudy, Medtronic Co. Dr. Cannon has received research grants/support from Accumetrics , AstraZeneca , GlaxoSmithKline , Intekrin Therapeutics , Merck , and Takeda ; is on the advisory board of Bristol-Myers Squibb/Sanofi, Novartis, and Alnylam; and is a clincal advisor with equity in Automedics Medical Systems. Dr. Fonarow has received honoraria from Merck and Bristol-Myers Squibb/Sanofi. Dr. Klein is on the Speakers' Bureau of Pfizer, Lilly, and Daiichi-Sankyo. Dr. Masoudi has contracts with the ACCF and the Oklahoma Foundation for Medical Quality. Dr. McKay is an ACC-NCDR Senior Medical Officer. Dr. Peterson has received research support from Bristol-Myers Squibb/Sanofi , Merck/Schering-Plough , Lilly , and Johnson & Johnson . Dr. Rumsfeld is the Chief Science Officer for the NCDR. Funding Information: The NCDR ACTION Registry-GWTG is a program of the American College of Cardiology and the American Heart Association that receives funding from the Merck/Schering-Plough Corporation and Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership . The CathPCI registry does not receive external funding. For complete author disclosures, please see the end of this paper. ",

year = "2010",

month = jul,

day = "20",

doi = "10.1016/j.jacc.2010.05.008",

language = "English (US)",

volume = "56",

pages = "254--263",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention

AU - Roe, Matthew T.

AU - Messenger, John C.

AU - Weintraub, William S.

AU - Cannon, Christopher P.

AU - Fonarow, Gregg C.

AU - Dai, David

AU - Chen, Anita Y.

AU - Klein, Lloyd W.

AU - Masoudi, Frederick A.

AU - McKay, Charles

AU - Hewitt, Kathleen

AU - Brindis, Ralph G.

AU - Peterson, Eric D.

AU - Rumsfeld, John S.

N1 - Funding Information: Dr. Roe has received research funding from Eli Lilly , Bristol-Myers Squibb , Sanofi-Aventis , and Merck/Schering-Plough ; and consulting fees/honoraria from GlaxoSmithKline, Novartis, Eli Lilly, Bristol-Myers Squibb, Sanofi-Aventis, Merck/Schering-Plough, and AstraZeneca. Dr. Messenger is a Principal Investigator for the Resolute substudy, Medtronic Co. Dr. Cannon has received research grants/support from Accumetrics , AstraZeneca , GlaxoSmithKline , Intekrin Therapeutics , Merck , and Takeda ; is on the advisory board of Bristol-Myers Squibb/Sanofi, Novartis, and Alnylam; and is a clincal advisor with equity in Automedics Medical Systems. Dr. Fonarow has received honoraria from Merck and Bristol-Myers Squibb/Sanofi. Dr. Klein is on the Speakers' Bureau of Pfizer, Lilly, and Daiichi-Sankyo. Dr. Masoudi has contracts with the ACCF and the Oklahoma Foundation for Medical Quality. Dr. McKay is an ACC-NCDR Senior Medical Officer. Dr. Peterson has received research support from Bristol-Myers Squibb/Sanofi , Merck/Schering-Plough , Lilly , and Johnson & Johnson . Dr. Rumsfeld is the Chief Science Officer for the NCDR. Funding Information: The NCDR ACTION Registry-GWTG is a program of the American College of Cardiology and the American Heart Association that receives funding from the Merck/Schering-Plough Corporation and Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership . The CathPCI registry does not receive external funding. For complete author disclosures, please see the end of this paper.

PY - 2010/7/20

Y1 - 2010/7/20

KW - NCDR

KW - acute myocardial infarction

KW - percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=77955641943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955641943&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2010.05.008

DO - 10.1016/j.jacc.2010.05.008

M3 - Article

C2 - 20633817

AN - SCOPUS:77955641943

SN - 0735-1097

VL - 56

SP - 254

EP - 263

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 4

ER -

Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this